Soleno Therapeutics Inc. (SLNO) said that it has priced underwritten public offering of 3 million shares of its common stock at $46.00 per share.SLNO closed Thursday's regular trading at $49.23 up $1.69 or 3.55%. But in the after-hours trading the stock dropped $3.23 or 6.56%.The company expects the gross proceeds from the public offering to be about $138.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Soleno Therapeutics Inc.（SLNO）表示，已将其300万股普通股的承销公开发行定价为每股46.00美元。SLNO周四的常规交易收于49.23美元，上涨1.69美元，涨幅3.55%。但在盘后交易中，该股下跌3.23美元，跌幅6.56%。该公司预计，在扣除承销折扣和佣金以及其他预计的发行费用之前，公开发行的总收益约为1.38亿美元。Soleno还授予承销商30天的期权，以公开发行价格（扣除承销折扣和佣金）购买多达45万股普通股。

.

.

The public offering is expected to close on or about May 7, 2024.Soleno noted that it plans to use the net proceeds from the offering to fund its current research and development efforts primarily focused on advancing its lead candidate, DCCR tablets for the treatment of Prader-Willi Syndrome, and to provide for general corporate purposes.

此次公开募股预计将于2024年5月7日左右结束。Soleno指出，它计划利用此次募股的净收益来资助其目前的研发工作，主要集中在推进其主要候选药物DCCR片剂，用于治疗Prader-Willi综合征，并为一般企业目的提供资金。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股